CRIS OUT-BACK PROGRAMME 2021 Researcher: Diego Benito Institution: Home: Universidad de Navarra, SPAIN – HOST: Massachusetts General Hospital Cancer Center (USA) Ovarian cancer has a 5-year survival rate of just 40%, due to its late diagnosis and aggressiveness. Although immunotherapy is showing good results in other types of tumours, in ovarian cancer the results are
CRIS OUT-BACK PROGRAMME 2021 Researcher: Rebeca González Institution:Home: INSTITUTO DE NEUROCIENCIAS CSIC-UMH, SPAIN – Host: Centre Méditerranéen de médecine moléculaire, France Melanoma is a very aggressive type of skin cancer experienced by more than 6000 people a year in Spain. It is the most aggressive skin tumour and most often metastasises. If metastasis occurs, in
CRIS POST-DOC TALENT PROGRAMME 2021 Researcher: Dra. Blanca Majem Cavaller Institution:Institut de Recerca Biomèdica (IRB), Barcelona Introduction: Tumour metastases represent the greatest challenge in cancer research. More than 90% of tumour deaths occur because of the consequences of metastases, yet a great deal is still unknown about the mechanisms that produce metastases and how to
CRIS POST-DOC TALENT PROGRAMME 2021 Researcher: Dra. Ceres Fernández Rozadilla Institution:Instituto de Investigación Sanitaria de Santiago de Compostela Colon or bowel cancer is the most diagnosed form of cancer in Spain (43,500 cases per year) and the second highest cause of death from cancer (16,500 people a year) after lung cancer. It is a complex
CRIS EXCELLENCE PROGRAMME 2021 Researcher: Dr. Arkaitz Carracedo Institution:CIC Biogune, Bilbao Introduction: Prostate cancer is the most prevalent form of cancer in men, causing more than 80,000 deaths a year in the European Union. Although most respond to treatments, these tumours have certain characteristics that make them a real medical challenge. On the one hand,
CRIS EXCELLENCE PROGRAMME 2021 Researcher: Dr. Aleix Prat Institution: Hospital Clínic, Barcelona Introduction: Breast cancer remains one of the biggest challenges in cancer research. 1 out of 8 women will develop breast cancer at some time in their lives. Breast tumours are generally classified according to whether or not the tumour cells possess certain molecules
CRIS CLINICAL TALENT PROGRAMME 2021 Researcher: Dra. Nuria Romero Laorden Institution: Hospital de La Princesa, Madrid Introduction: We tend to see prostate cancer as relatively benign and curable, but approximately 10% of patients have metastases and do not respond to usual treatments. These patients have a life expectancy of less than 3 years, and account
CRIS CLINICAL TALENT PROGRAMME 2021 Researcher: Dra. Ana Jiménez Ubieto Institution: Hospital Universitario 12 de octubre, Madrid Introduction: Follicular lymphoma is one of the most common types of blood cancer. Although it tends to be relatively non-aggressive, it still currently has no cure. In addition, a significant number of patients (between 15% and 20%) relapse
Researcher: Dr. Bruno Paiva Center: : Clínica Universidad de Navarra Introduction: Multiple myeloma is the second most common blood cancer. It has extremely high mortality rates and there is still no cure for it. Myeloma, like other blood diseases, goes through a benign stage called Monoclonal Gammopathy of Undetermined Significance (MGUS) which, in most cases, does not progress to serious disease. However,
Researcher: Dra. María Casanova Center: CNIO, Madrid Introduction: At present, there are no adequate treatments for triple negative breast cancer, an extremely aggressive cancer with high mortality rates. One of the most significant complications of this cancer is that 60% of patients develop metastases, the causes of which remain largely unknown. Advances in understanding the immune system have enabled the following to be identified: a highly varied and heterogeneous group of tumour cells (called myeloid cells), which occasionally behave abnormally, stop rejection of the tumour and may have a crucial function in the